Niloofar Davoodi

Director Cell Therapy CMC • Takeda

Dr Niloofar Davoodi holds dual degrees of PharmD in Pharmaceutical Biotechnology and PhD in Molecular Cell Biology.  She has 20 years of experience in research, development, manufacturing, and supply of bio-pharmaceutical products.

Currently, Niloofar is the Director of Cell Therapy CMC at Takeda (Switzerland) and a member of Global Manufacturing Sciences Leadership Team.  In her current role she has overall responsibility for defining and execution of global CMC strategy throughout all lifecycle stages of Cell Therapy products.

Prior to Takeda, Niloofar was 14 years at Novartis (Switzerland) where she held various positions of increasing responsibilities in different global functions in Research, Quality, Analytical Science & Technology, Manufacturing Science & Technology as well as Regulatory CMC.  She was the Regulatory Science & Project Lead for the Technology Transfer of Novartis CAR-T therapy product to the first commercial CGT manufacturing facility of Novartis in Europe

Also speaking

Amro Eid

Ian Rees

Inspectorate Strategy and Innovation • MHRA

Ryan Hicks

Senior Director – Head of Bioscience Cell Therapy, BioPharmaceuticals, R&D Cell Therpay • AstraZeneca

Event Info


Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.

2022 Post-Event Report

Download the post-event report for Advanced Therapies Europe 2022.